{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:02:08Z","timestamp":1782298928487,"version":"3.54.5"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1443,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1365-2036.2011.04840.x","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T06:18:47Z","timestamp":1316413127000},"page":"1115-1122","source":"Crossref","is-referenced-by-count":32,"title":["Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis"],"prefix":"10.1111","volume":"34","author":[{"given":"L.","family":"Leifeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pf\u00fctzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Marakhouski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greinwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Kruis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,19]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based Consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohn Colitis"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB4|cit4","first-page":"1338","article-title":"A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults","volume":"91","author":"Kam","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB5|cit5","first-page":"1867","article-title":"A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jcgh.2003.50006","article-title":"The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine","volume":"1","author":"Kruis","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2036.2005.02312.x","article-title":"A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis","volume":"21","author":"Marakhouski","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gut.2008.154302","article-title":"Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised non-inferiority trial","volume":"58","author":"Kruis","year":"2009","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2036.2006.02861.x","article-title":"Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis","volume":"23","author":"Gibson","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1046\/j.1365-2036.2003.01564.x","article-title":"Gastrointestinal transit and release of 5-aminosalicylic acid from (153)Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers","volume":"17","author":"Brunner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2006.02846.x","article-title":"Systematic review: the use of mesalazine in inflammatory bowel disease","volume":"23","author":"Bergman","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","article-title":"Once-daily, high-concentration MMX mesalamine in active ulcerative colitis","volume":"132","author":"Kamm","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","article-title":"Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis","volume":"5","author":"Lichtenstein","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2036.2007.03361.x","article-title":"MMX Multi Matrix\u2122 mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials","volume":"26","author":"Sandborn","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.MIB.0000158386.25660.1e","article-title":"A new oral delivery system for 5-ASA: preliminary clinical findings for MMX","volume":"11","author":"Prantera","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.03069.x","article-title":"Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence","volume":"24","author":"Desreumaux","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am J Med"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","article-title":"Systematic review: adherence issues in the treatment of ulcerative colitis","volume":"23","author":"Kane","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1572-0241.2003.07522.x","article-title":"Patient nonadherence to medication in inflammatory bowel disease","volume":"98","author":"Sewitch","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2036.2003.01648.x","article-title":"Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease","volume":"18","author":"Shale","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/j.1572-0241.1999.01200.x","article-title":"Increasing patient adherence to gastroenterology treatment and prevention regimens","volume":"94","author":"Levy","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00042737-199612000-00009","article-title":"Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire","volume":"8","author":"Moody","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04840.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/gut.2005.070896","article-title":"5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study","volume":"54","author":"van Staa","year":"2005","journal-title":"Gut"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04840.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04840.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T17:20:31Z","timestamp":1613150431000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/j.1365-2036.2011.04840.x"}},"subtitle":["Mesalazine granules in distal ulcerative colitis"],"short-title":[],"issued":{"date-parts":[[2011,9,19]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04840.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9,19]]}}}